NEUROCOGNITIVE FUNCTION (NCF) OUTCOMES OF RTOG FOUNDATION 3508: A PHASE 3 TRIAL OF ABT-414 WITH CONCURRENT CHEMORADIATION AND ADJUVANT TEMOZOLOMIDE IN PATIENTS WITH EGFR-AMPLIFIED NEWLY DIAGNOSED GBM Conference

Wefel, Jeffrey S, Won, Minhee, Lassman, Andrew et al. (2020). NEUROCOGNITIVE FUNCTION (NCF) OUTCOMES OF RTOG FOUNDATION 3508: A PHASE 3 TRIAL OF ABT-414 WITH CONCURRENT CHEMORADIATION AND ADJUVANT TEMOZOLOMIDE IN PATIENTS WITH EGFR-AMPLIFIED NEWLY DIAGNOSED GBM . NEURO-ONCOLOGY, 22 54-54.

Industry Collaboration International Collaboration

cited authors

  • Wefel, Jeffrey S; Won, Minhee; Lassman, Andrew; Stern, Yaakov; Wang, Tony; Aldape, Kenneth; Armstrong, Terri; Vogelbaum, Michael; Sulman, Erik; Moazami, Golnaz; Macsai, Marian; Gilbert, Mark; Bain, Earle; Blot, Vincent; Gan, Hui; Preusser, Matthias; Ansell, Peter; Samanta, Suvajit; Kundu, Madan; Seidel, Clemens; de Vos, Filip; Hsu, Sigmund; Cardona, Andres; Lombardi, Giuseppe; Bentsion, Dmitry; Peterson, Richard; Gedye, Craig; Lebrun-Frenay, Christine; Wick, Antje; Pugh, Stephanie; Curran, Walter; Mehta, Minesh

authors

date/time interval

  • November 19, 2020 -

publication date

  • November 1, 2020

published in

keywords

  • Clinical Neurology
  • Life Sciences & Biomedicine
  • Neurosciences & Neurology
  • Oncology
  • Science & Technology

Location

  • ELECTR NETWORK

Conference

  • 25th Virtual Annual Scientific Meeting and Education Day of the Society-for-Neuro-Oncology (SNO)

publisher

  • OXFORD UNIV PRESS INC

start page

  • 54

end page

  • 54

volume

  • 22